---
title: "Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281128317.md"
description: "Sanofi has received conditional marketing authorization from the European Commission for Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 and older with a minimum weight of 40 kg. This authorization is contingent on completing a confirmatory study. The approval follows a positive opinion from the CHMP and is based on safety and efficacy results from clinical studies. Rezurock is also approved in 20 other countries. Sanofi shares closed at 81.90 euros, down 0.11%."
datetime: "2026-03-31T05:34:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281128317.md)
  - [en](https://longbridge.com/en/news/281128317.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281128317.md)
---

# Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock

Add  as your preferred news source on Google

 Add Now

Sanofi (SNY,SAN.PA) said the European Commission has granted a conditional marketing authorisation for Rezurock or belumosudil for the treatment of chronic graft-versus-host disease in adults and in children aged 12 years and older with a body weight of at least 40 kg. The conditional marketing authorisation is contingent on completion of a confirmatory, randomised, controlled study. This follows the positive opinion by the CHMP issued on 30 January 2026.

The company said the approval is based on safety and efficacy results from several clinical studies and real-world evidence. In addition to the EU, Rezurock is approved in 20 countries.

At last close, shares of Sanofi were trading at 81.90 euros, down 0.11%.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [688108.CN](https://longbridge.com/en/quote/688108.CN.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)

## Related News & Research

- [Sanofi: Information concerning the total number of voting rights and shares - April 2026](https://longbridge.com/en/news/286946199.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)